Pedro Gonzales, MD, MAS

Head of Clinical Research Resource Unit
Impacta Peru Clinical Trials Unit
CRS Coordinator, Site 11301
Asociacion Civil Impacta Salud y Educacion
Av. Almirante Miguel Grau 1010, Barranco, Lima 04, Peru


Dr. Gonzales hold his BS in Medicine (1997) and MD (1998) from Universidad Peruana Cayetano Heredia, Lima, Peru. He holds Master in Advance Studies (M.A.S.) in Clinical Research from the University of California, San Francisco. He joined Association Civil Impacta Salud y Education in 2004 and have participated in several clinical trials as Co-Investigator and Investigator of Record for the HIV Prevention Trial Network (HPTN), the HIV Vaccine Trail Network (HVTN), the AIDS Clinical Trial Group (ACTG), the Microbicides Trial Network (MTN), and INSIGHT. Dr. Gonzales is the Site Principal Investigator for the MTN 017 and for the Randomized Placebo-Controlled Clinical Trial to assess the impact of extended-release naltrexone on HIV treatment outcomes among HIV-1 infected men and transgender women with alcohol use disorders in Lima, Peru. He was a member of the Network Evaluation Committee of the HVTN and a member of the Site Management and Clinical Care and the Translational and Drug Development committees, both from the ACTG research network. Currently, He is an Investigator of several ACTG, MTN, HPTN and HVTN trials and member of ACTG, HPTN and HVTN scientific committees and working groups.

Research Interest

His research interests include: HIV prevention: Combination prevention, PrEP, Vaccines, Treatment as Prevention, HIV treatment, HIV Comorbidities: Hepatitis and TB, Substance use and HIV.

Scientific Activities

Other Experience and Professional Memberships

• 1998: Member, Colegio Medico del Peru No. 32366 ( Peruvian Medical College)
• 2007-2009: Network Evaluation Committee member, HIV Vaccine Trials Network
• 2007-2009: Site Management and Clinical Care Committee (SMCCC) member, AIDS Clinical Trial Group(ACTG)
• 2007-2009: Translational Research and Drug Development member (SMCCC representative), ACTG
• 2011: International AIDS Society Member
• 2014: Efficacy Trials Working Group, HIV Vaccine Trial Network
• 2014: Substance Use Scientific Committee (SUSC), HIV Prevention Trial Network
• 2014: Site Management and Clinical Care Comittee (SMCCC), AIDS Clinical Trial Group
• 2014: Performace Evaluation Comitte (PEC), AIDS Clinical Trial Group


Selected Peer-reviewed Publications

1. Vagenas P, Lama JR, Ludford KT, Gonzales P, Sanchez J, Altice FL. A systematic review of alcohol use and sexual risk-taking in Latin America. Rev Panam Salud Publica. 2013; 34(4): 267-274.
2. Vagenas P, Ludford KT, Gonzales P, et al. Being unaware of being HIV-infected is associated with alcohol use disorders and high-risk sexual behaviors among men who have sex with men in Peru. AIDS Behav. 2014; 18(1):120-127. doi: 10.1007/s10461-013-0504-2
3. Tang EC, Sobieszczyk ME, Shu E, Gonzales P, Sanchez J, Lama JR. Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk MSM in Lima, Peru. AIDS Res Hum Retroviruses. 2013. doi: 10.1089/AID.2013.0212
4. Ludford KT, Vagenas P, Lama JR, et al. Screening for drug and alcohol use disorders and their association with HIV-related sexual risk behaviors among men who have sex with men in Peru. PLoS One. 2013; 8(8): e69966. doi: 10.1371/journal.pone.0069966
5. Michael V, Peinado J, Segura E, et al. Socialization patterns and their associations with unprotected anal intercourse, hiv, and syphilis among high-risk men who have sex with men and transgender women in peru. AIDS and Behavior. 2014; 18(10): 2030-2039. doi: 10.1007/s10461-014-0787-y.
6. Ferro EG, Weikum D, Vagenas P, et al. Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru. AIDS Care. 2014; 3: 1-12. doi: 10.1080/09540121.2014.963013
7. Brown SE, Vagenas P, Konda KA, et al. Men who have sex with men in peru: acceptability of medication-assisted therapy for treating alcohol use disorders. Am J Mens Health. 2015; pii: 1557988315576775. doi: 10.1177/1557988315576775